No Evidence for Benefits of 'Vaginal Seeding'

Share this content:
No Evidence for Benefits of 'Vaginal Seeding'
No Evidence for Benefits of 'Vaginal Seeding'

FRIDAY, Feb. 26, 2016 (HealthDay News) -- The increasingly common practice of "vaginal seeding" in infants born by cesarean section is not without risks, according to an editorial published online Feb. 23 in The BMJ.

Aubrey J. Cunnington, B.M.B.Ch., Ph.D., from Imperial College London, and colleagues discuss the increasingly common practice of vaginal seeding, involving use of a gauze swab to transfer maternal vaginal fluid and vaginal microbiota onto an infant born by cesarean section. Vaginal seeding might restore the microbiota of infants born by cesarean section to a more "natural" state.

The authors note that delivery by cesarean section is associated with increased risk of certain diseases, which are also associated with alterations in the microbiota. Although the human microbiota can be manipulated to benefit health, there is currently no clear evidence of benefit for vaginal seeding. Newborns may develop severe infections from exposure to vaginal commensals and pathogens that the mother may carry, including group B streptococcus, herpes simplex virus, Chlamydia trachomatis, and Neisseria gonorrhoeae. These pathogens might also be transmitted on a vaginal swab. In the absence of evidence of benefit or guidelines to ensure procedural safety, the authors do not recommend performing vaginal seeding.

"Parents should be advised to mention that they performed vaginal seeding if their baby becomes unwell because this may influence a clinician's assessment of the risk of serious infection," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »